Tarsus Pharmaceuticals (TARS) Corporate presentation summary

Commercial portfolio and pipeline

• Commercial-stage biopharma with one FDA-approved product (LYMPHIR) and two late-stage programs (Mino-Lok, Halo-Lido).

• LYMPHIR launched December 2025 for relapsed/refractory cutaneous T-cell lymphoma (CTCL), generating $5.6M in first four months.

• Mino-Lok completed Phase 3, showing superiority in catheter salvage for bloodstream infections; addresses a $1.8B global market.

• Halo-Lido completed Phase 2b for hemorrhoids, with positive results and a large unmet need (>10M patients).

• Recent financings ($41.5M) extend cash runway into Q4 2026.

LYMPHIR commercialization and market traction

• Achieved broad payer access, with 83% of target accounts on formulary or in review and near 100% coverage.

• Early adoption at target institutions, repeat ordering, and no reimbursement denials reported.

• Commercial supply established in the U.S. and international expansion underway via Named Patient Programs.

• Distribution agreements with major U.S. specialty distributors and ex-U.S. partners covering 19 markets.

• Permanent CMS J-code in place, streamlining provider ordering and payment.

Competitive positioning and growth opportunities

• LYMPHIR offers a differentiated mechanism of action, targeting IL-2 receptor and depleting Tregs, with no cumulative toxicity.

• Addresses limitations of current CTCL therapies, providing rapid response and skin relief.

• Multi-layered protection: 12 years BLA exclusivity, orphan drug exclusivity, complex manufacturing, and pending patents.

• Investigator-led studies support expansion into CAR-T conditioning and combination with checkpoint inhibitors.

• Label expansion potential in PTCL and other cancers; denileukin diftitox approved for PTCL in Japan.